Bright Green Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lynn Stockwell
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 401 East Las Olas Boulevard Fort Lauderdale FL United States of America 33301
- IPO Date
- Feb 18, 2025
- CIK
- 0001886799
- Website
- brightgreen.us
- Similar Companies
- Business
- Bright Green Corporation, a producer and exporter of legal cannabis, cannabis extracts, and tetrahydrocannabinol for research, manufacturing, and pharmaceutical applications, operates primarily in the United States with facilities designed for high‑tech cultivation and processing; the company engages in supplying cannabis and related products to DEA‑registered pharmaceutical companies for medicinal cannabis and clinical research, as well as for export to international markets. Founded in 2019 and headquartered in Grants, New Mexico, Bright Green positions its activities within the broader cannabis, biotechnology, and pharmaceutical sectors, coupling cultivation and extraction with research and development, manufacturing, and supply to regulated channels. The company’s core operations span cultivation facilities, processing lines for cannabis extracts, formulation and product development capabilities, regulatory compliance, and international export logistics, supported by ongoing expansion initiatives and strategic reorganizations in recent years. Main products and services: cannabis cultivation and production; cannabis extracts and concentrates; tetrahydrocannabinol (THC) products for research, manufacturing, and medical use; regulatory compliance and DEA registration-enabled supply for pharmaceutical applications; international export of cannabis and cannabis preparations; research and development collaborations and clinical trial support; product formulation and manufacturing services; supply chain and logistics services for regulated cannabis markets. Latest major company changes: restructuring and plan for equity recapitalization under Chapter 11 proceedings with a Restructuring Security Agreement and Disclosure Statement, enabling new equity to satisfy approved creditor claims while preserving existing shareholder interests; ongoing strategic shifts toward enhanced capital structure and creditor alignment; advancement of expansion plans and capacity improvements to support research, development, and manufacturing scale; continued efforts to secure regulatory approvals and DEA registration for broader production and export activities; renewed emphasis on aligning operations with compliance and governance standards following reorganizations. Additional context: Bright Green operates in the integrated sectors of cannabis production, cannabis extracts, and regulated medical cannabis manufacturing, with a focus on serving pharmaceutical, research, and international export markets; target customers include DEA‑registered pharmaceutical companies, clinical research organizations, contract manufacturers, and international buyers requiring regulated cannabis inputs and preparations; geographic footprint centers on the United States, with potential international trade activities subject to regulatory approvals; founding year 2019; headquarters in Grants, New Mexico; notable subsidiaries or reorganizations reflect the company’s restructuring path and capital‑structure optimization in recent years.
Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
Wedbush's Ives Sees 'Bright Green Light' for Tech Stocks
PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A
Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman
Is Media And Entertainment A Growth Sector? These 3 Legacy Giants Are Flashing Bright Green
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.
Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
CEO UPDATE
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.
BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS
BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.